VIVUS, Inc. (NASDAQ:VVUS) announced that J. Martin Carroll, Mark B. Logan and Robert N. Wilson have decided not to stand for re-election when their terms expire at the Annual Meeting of Stockholders, to be held on June 20, 2014. VIVUS, Inc. (NASDAQ:VVUS) shares after opening at $5.10 moved to $5.20 on last trade day and at the end of the day closed at $4.99. Company price to sales ratio in past twelve months was calculated as 6.36 and price to cash ratio as 1.50. VIVUS, Inc. (NASDAQ:VVUS) showed a negative weekly performance of -17.38%.
On March 5, 2014 ArQule, Inc. (NASDAQ:ARQL) issued a press release announcing its results of operations for the fiscal quarter and year ended December 31, 2013. ArQule, Inc. (NASDAQ:ARQL) shares advanced 5.82% in last trading session and ended the day on $2.00. ARQL return on equity ratio is recorded as -33.60% and its return on assets is -20.70%. ArQule, Inc. (NASDAQ:ARQL) yearly performance is -27.27%.
Heat Biologics, Inc. (NASDAQ:HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced that the Company has submitted its revised Phase 2 clinical trial protocol for its HS-110 product candidate to the U.S. Food and Drug Administration for the treatment of patients with non-small cell lung cancer (NSCLC). Heat Biologics Inc. (NASDAQ:HTBX) shares moved down -2.64% in last trading session and was closed at $5.90, while trading in range of $5.81 – $6.25. Heat Biologics Inc. (NASDAQ:HTBX) year to date (YTD) performance is -16.90%.
On March 31, 2014, Concert Pharmaceuticals, Inc. (NYSE:JMPC) announced its financial results for the fiscal year ended December 31, 2013. Concert Pharmaceuticals Inc. (NYSE:JMPC) weekly performance is -10.51%. On last trading day company shares ended up $25.21. Concert Pharmaceuticals Inc. (NYSE:JMPC) distance from 50-day simple moving average (SMA50) is -14.14%. Analysts mean target price for the company is $27.00.